FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092226564> ?p ?o ?g. }

• W3092226564 endingPage "4606" @default.
• W3092226564 startingPage "4606" @default.
• W3092226564 abstract "The hormonal luminal-A is the most pre-dominant sub type of breast cancer (BC), and it is associated with a high level of cyclin D1 in Saudi patients. Tamoxifen is the golden therapy for hormonal BC, but resistance of cancer cells to tamoxifen contributes to the recurrence of BC due to many reasons, including high levels of AIB1 and cyclin D1. Overcoming drug resistance could be achieved by exploring alternative targetable therapeutic pathways and new drugs or combinations. The objective of this study was to determine the differentially enriched pathways in 12 samples of Saudi women diagnosed with luminal-A using the PamChip peptide microarray-based kinase activity profiling, and to compare the activity of HAA2020 and dinaciclib with tamoxifen in singles and combinations in the MCF7 luminal-A cell line. Our results of network and pathway analysis of the 12 samples highlighted the importance of VEGFR and CDKs in promoting luminal-A breast cancer. The activation of VEGF signaling via VEGFR-2 leads to activation of PI3K/AKT kinases and an increase of cell survival, and leads to activation of Hsp90, which induces the phosphorylation of FAK1, resulting in cytoskeleton remodeling. PLC-gamma 1 is also activated, leading to FAK-2 and PKC activation. Notably, the G1/S cell cycle phases and phosphorylation processes contribute to the top seven tumorigenesis processes in the 12 samples. Further, the MTT combination of HAA2020 and dinaciclib showed the best combination index (CI), was more clonogenic against MCF7 cells compared to the other combinations, and it also showed the best selectivity index (SI) in normal MRC5 cells. Interestingly, HAA2020 and dinaciclib showed a synergistic apoptotic and G1 cell cycle effect in MCF7 cells, which was supported by their synergistic CDK2, cyclin D1, and PCNA inhibition activities. Additionally, the combination showed VEGFR-2 and Hsp90 inhibition activities in MCF7 cells. The results show the significance of targeting VEGFR-2 and cyclin D1 in Saudi luminal-A breast cancer patients, and the effect of combining HAA2020 and dinaciclib on those targets in the MCF7 model. It also warrants further preclinical and in vivo investigations for the combination of HAA2020 and dinaciclib as a possible future second-line treatment for luminal-A breast cancers." @default.
• W3092226564 created "2020-10-15" @default.
• W3092226564 creator A5001178856 @default.
• W3092226564 creator A5004512336 @default.
• W3092226564 creator A5018442918 @default.
• W3092226564 creator A5028403012 @default.
• W3092226564 creator A5056209135 @default.
• W3092226564 creator A5066567170 @default.
• W3092226564 date "2020-10-10" @default.
• W3092226564 modified "2023-10-07" @default.
• W3092226564 title "Significance of Targeting VEGFR-2 and Cyclin D1 in Luminal-A Breast Cancer" @default.
• W3092226564 cites W1626929029 @default.
• W3092226564 cites W1971864286 @default.
• W3092226564 cites W1977584584 @default.
• W3092226564 cites W1977789013 @default.
• W3092226564 cites W2018702616 @default.
• W3092226564 cites W2020166868 @default.
• W3092226564 cites W2040080013 @default.
• W3092226564 cites W2050831491 @default.
• W3092226564 cites W2058970657 @default.
• W3092226564 cites W2069683864 @default.
• W3092226564 cites W2071370708 @default.
• W3092226564 cites W2072568217 @default.
• W3092226564 cites W2077037832 @default.
• W3092226564 cites W2080073879 @default.
• W3092226564 cites W2085303528 @default.
• W3092226564 cites W2086407765 @default.
• W3092226564 cites W2105001984 @default.
• W3092226564 cites W2117692326 @default.
• W3092226564 cites W2224812643 @default.
• W3092226564 cites W2235908181 @default.
• W3092226564 cites W2347000573 @default.
• W3092226564 cites W2355828512 @default.
• W3092226564 cites W2420100166 @default.
• W3092226564 cites W2482607006 @default.
• W3092226564 cites W2491062142 @default.
• W3092226564 cites W2598611164 @default.
• W3092226564 cites W2756562465 @default.
• W3092226564 cites W2770369177 @default.
• W3092226564 cites W2770920742 @default.
• W3092226564 cites W2774743554 @default.
• W3092226564 cites W2886238883 @default.
• W3092226564 cites W2889646458 @default.
• W3092226564 cites W2907944423 @default.
• W3092226564 cites W2946455326 @default.
• W3092226564 cites W2966387629 @default.
• W3092226564 cites W2972303137 @default.
• W3092226564 cites W2979896589 @default.
• W3092226564 cites W2980047382 @default.
• W3092226564 cites W2981746967 @default.
• W3092226564 cites W2992659008 @default.
• W3092226564 cites W2995224844 @default.
• W3092226564 cites W3006780872 @default.
• W3092226564 cites W3006887404 @default.
• W3092226564 cites W3010714596 @default.
• W3092226564 cites W3013196158 @default.
• W3092226564 cites W3021855132 @default.
• W3092226564 cites W3033560629 @default.
• W3092226564 cites W3044230569 @default.
• W3092226564 cites W4238991694 @default.
• W3092226564 doi "https://doi.org/10.3390/molecules25204606" @default.
• W3092226564 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7594023" @default.
• W3092226564 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33050377" @default.
• W3092226564 hasPublicationYear "2020" @default.
• W3092226564 type Work @default.
• W3092226564 sameAs 3092226564 @default.
• W3092226564 citedByCount "16" @default.
• W3092226564 countsByYear W30922265642021 @default.
• W3092226564 countsByYear W30922265642022 @default.
• W3092226564 countsByYear W30922265642023 @default.
• W3092226564 crossrefType "journal-article" @default.
• W3092226564 hasAuthorship W3092226564A5001178856 @default.
• W3092226564 hasAuthorship W3092226564A5004512336 @default.
• W3092226564 hasAuthorship W3092226564A5018442918 @default.
• W3092226564 hasAuthorship W3092226564A5028403012 @default.
• W3092226564 hasAuthorship W3092226564A5056209135 @default.
• W3092226564 hasAuthorship W3092226564A5066567170 @default.
• W3092226564 hasBestOaLocation W30922265641 @default.
• W3092226564 hasConcept C117262875 @default.
• W3092226564 hasConcept C11960822 @default.
• W3092226564 hasConcept C121608353 @default.
• W3092226564 hasConcept C124320809 @default.
• W3092226564 hasConcept C126322002 @default.
• W3092226564 hasConcept C1491633281 @default.
• W3092226564 hasConcept C184235292 @default.
• W3092226564 hasConcept C185592680 @default.
• W3092226564 hasConcept C199835354 @default.
• W3092226564 hasConcept C2777176818 @default.
• W3092226564 hasConcept C2778019345 @default.
• W3092226564 hasConcept C2778695046 @default.
• W3092226564 hasConcept C2780333294 @default.
• W3092226564 hasConcept C29537977 @default.
• W3092226564 hasConcept C502942594 @default.
• W3092226564 hasConcept C530470458 @default.
• W3092226564 hasConcept C55493867 @default.
• W3092226564 hasConcept C71924100 @default.
• W3092226564 hasConcept C75217442 @default.
• W3092226564 hasConcept C86803240 @default.

• next